Engineered Immune Cells Could Detect and Treat Alzheimer's Before Symptoms Appear
Buck Institute scientist engineers CAR-Treg cells to detect amyloid plaques and release Alzheimer's antibody exactly where needed.
Summary
Researchers at the Buck Institute are engineering immune cells to act as microscopic doctors inside the body. Chaska Walton, PhD, is developing synthetic immune cells — including programmable CAR-Treg cells — that can detect amyloid beta plaques, the hallmark of Alzheimer's disease, and automatically release Leqembi, an FDA-approved plaque-clearing antibody, precisely at the site of pathology. Unlike conventional drugs that spread throughout the body, these engineered cells operate at the single-cell level, potentially catching disease years before symptoms emerge. Funded by a rare $2.4 million NIH Transformative Research Award, this work sits at the intersection of synthetic biology, neuroscience, and translational medicine, and could fundamentally change how neurodegenerative diseases are detected and treated.
Detailed Summary
Alzheimer's disease remains one of the most devastating and treatment-resistant conditions associated with aging. A core problem is timing: by the time symptoms appear, neurodegeneration has often been progressing for years or even decades. Conventional drugs also lack precision, distributing throughout the body rather than targeting diseased tissue directly. A new approach being developed at the Buck Institute aims to solve both problems simultaneously.
Chaska Walton, PhD, a research scientist in Julie Andersen's lab, is engineering immune cells to function as autonomous, living therapeutics. The breakthrough centers on genetically modifying cells so they can detect amyloid beta senile plaques — a defining feature of Alzheimer's pathology — and respond by producing and secreting Leqembi, the FDA-approved amyloid-clearing antibody. This creates a closed-loop biological system: detection and treatment happen at the microscopic level, continuously and automatically.
The platform includes programmable CAR-Treg cells and smart cell delivery systems. These engineered cells can theoretically identify disease signals far earlier than any clinical test, since they operate at the cellular scale around the clock. Walton describes this as "shrinking your doctor to 20 nanometers" — a vivid illustration of the precision involved. A human physician must wait for measurable symptoms; an engineered cell does not.
This research is supported by one of only nine NIH Transformative Research Awards granted nationally, a $2.4 million grant reflecting the high-risk, high-reward nature of the science. Walton's background spans psychology, neuroscience, and molecular bioscience, and their earlier doctoral work challenged dogma by showing mature neurons can re-enter the cell cycle.
Caveats are significant: this work is early-stage and largely pre-clinical. Translation to human therapies involves substantial regulatory, safety, and delivery hurdles. Still, for longevity-focused readers, this represents a meaningful frontier — the possibility that neurodegeneration could one day be intercepted before it becomes symptomatic.
Key Findings
- Immune cells engineered to detect amyloid beta plaques and auto-release FDA-approved antibody Leqembi at disease sites.
- CAR-Treg cell platforms may enable earlier Alzheimer's detection than any current clinical diagnostic tool.
- Engineered cells operate continuously at the microscopic level, potentially catching pathology years before symptoms emerge.
- Precision drug delivery at the single-cell level could reduce systemic side effects common in conventional Alzheimer's therapies.
- NIH awarded only 9 Transformative Research grants nationally; Walton received one worth $2.4 million for this work.
Methodology
This is a researcher profile and interview published by the Buck Institute, a credible and well-regarded aging research institution. It is not a peer-reviewed study but summarizes ongoing laboratory research by a funded NIH award recipient. Evidence basis is descriptive and qualitative, drawn from the scientist's own account of their work.
Study Limitations
No primary research paper is cited or linked; findings are self-reported by the researcher in an interview format. The technology is early-stage with no human trial data presented. Readers should seek peer-reviewed publications from Walton and the Andersen lab to assess the current evidence base.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.